Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Marlowe raises buyback plan as profits top forecasts

(Sharecast News) - Marlowe has raised its share buyback programme after delivering a "strong" performance over the financial year ended 31 March, with profits expected to be ahead of market forecasts. The company, which provides services that ensure regulatory compliance like installing fire detection systems, said continuing operations delivered £305m in revenues and £32.5m in adjusted EBITDA over the year - more or less in line with market expectations.

However, both figures were down substantially from last year after the £430m divestment of selected governance, risk and compliance (GRC) software and services assets and the demerger of its Occupational Health division.

However, adjusted pre-tax profit is estimated to come in at £18.5m, comfortably above the £16m consensus forecast.

As part of its GRC divestment, Marlowe returned £150m to shareholders by way of a special dividend last July, and launch a £75m share buyback programme which is now nearing completion. On Monday, the company announced plans to return a further £15m to shareholders.

In other news, Marlowe also announced the £6.2m acquisition of SludgeTek, an Andover-based specialist provider of waste management and manufacturing services.

"The acquisition further strengthens Marlowe's position as a leading provider of wastewater rental solutions and is highly complementary to the group's existing capabilities," the company said.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.